We are live on ! Find out more
BCLSI

Bain Capital Life Sciences Investors Portfolio holdings

AUM $1.11B
1-Year Est. Return 171.34%
This Fund
S&P 500
This Quarter Est. Return
+55.94%
1 Year Est. Return
+171.34%
3 Year Est. Return
+643.23%
5 Year Est. Return
+451.99%
10 Year Est. Return
–
AUM
$1.51B
AUM Growth
+$707M
Cap. Flow
+$262M
Cap. Flow %
17.39%
Top 10 Hldgs %
92.72%
Holding
24
New
1
Increased
2
Reduced
4
Closed
3

Top Buys

Rank Stock Value
1
HTFL
Heartflow Inc
HTFL
+$400M
2
CDTX
Cidara Therapeutics
CDTX
+$33.2M
3
XFOR icon
X4 Pharmaceuticals
XFOR
+$4.83M

Top Sells

Rank Stock Value
1
NUVL
Nuvalent
NUVL
+$110M
2
IRON icon
Disc Medicine
IRON
+$30.9M
3
DNTH icon
Dianthus Therapeutics
DNTH
+$29.8M
4
PHVS icon
Pharvaris
PHVS
+$2.71M
5
IVVD icon
Invivyd
IVVD
+$1.29M

Sector Composition

Rank Sector Weight
1 Healthcare 99.89%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
HTFL
1
Heartflow Inc
HTFL
$2.56B
$419M 27.81%
+12,448,158
New +$400M
NAMS icon
2
NewAmsterdam Pharma
NAMS
$3.32B
$305M 20.23%
10,719,110
– –
CDTX
3
DELISTED
Cidara Therapeutics
CDTX
$289M 19.2%
3,020,990
+520,310
+21% +$33.2M
PHVS icon
4
Pharvaris
PHVS
$2.42B
$79.4M 5.27%
3,181,275
-122,106
-4% -$2.71M
OLMA icon
5
Olema Pharmaceuticals
OLMA
$1.05B
$67M 4.45%
6,843,954
– –
SVRA icon
6
Savara
SVRA
$1.17B
$62.8M 4.17%
17,600,621
– –
DNTH icon
7
Dianthus Therapeutics
DNTH
$6.08B
$51.8M 3.44%
1,315,892
-1,166,358
-47% -$29.8M
SLDB icon
8
Solid Biosciences
SLDB
$894M
$48.8M 3.24%
7,911,669
– –
UPB
9
Upstream Bio Inc
UPB
$406M
$45.9M 3.05%
2,439,538
– –
RPID icon
10
Rapid Micro Biosystems
RPID
$85.2M
$28.2M 1.87%
8,434,560
– –
TNGX icon
11
Tango Therapeutics
TNGX
$4.41B
$22.8M 1.51%
2,712,008
– –
CABA icon
12
Cabaletta Bio
CABA
$455M
$22.6M 1.5%
9,677,125
– –
KYTX icon
13
Kyverna Therapeutics
KYTX
$486M
$20.2M 1.34%
3,368,370
– –
ANNX icon
14
Annexon
ANNX
$868M
$16M 1.06%
5,249,069
– –
XFOR icon
15
X4 Pharmaceuticals
XFOR
$434M
$8.33M 0.55%
2,436,588
+1,872,729
+332% +$4.83M
AVIR icon
16
Atea Pharmaceuticals
AVIR
$403M
$7.21M 0.48%
2,485,638
– –
XLO icon
17
Xilio Therapeutics
XLO
$60.8M
$3.85M 0.26%
326,201
– –
MRSN
18
DELISTED
Mersana Therapeutics
MRSN
$2.69M 0.18%
346,545
-2
-0% -$15
CCCC icon
19
C4 Therapeutics
CCCC
$402M
$2.47M 0.16%
1,111,910
– –
IPSC icon
20
Century Therapeutics
IPSC
$357M
$1.76M 0.12%
3,538,609
-1,871,752
-35% -$1.01M
NAMSW icon
21
NewAmsterdam Pharma Warrant
NAMSW
$79.1M
$1.71M 0.11%
100,000
– –
IRON icon
22
Disc Medicine
IRON
$2.99B
– –
-583,500
Closed -$30.9M
IVVD icon
23
Invivyd
IVVD
$201M
– –
-1,799,595
Closed -$1.29M
NUVL
24
DELISTED
Nuvalent
NUVL
– –
-1,447,267
Closed -$110M

Similar funds

SL
Sentinus LLC Oak Brook, Illinois $1.11B AUM 17.13% 1-Year Est. Return
JTWM
Jackson Thornton Wealth Management Montgomery, Alabama $1.11B AUM 22.53% 1-Year Est. Return
RWM
RKL Wealth Management Lancaster, Pennsylvania $1.11B AUM 18.99% 1-Year Est. Return
EIA
Emerald Investment Advisers Leola, Pennsylvania $1.11B AUM
HH
Hilltop Holdings Dallas, Texas $1.11B AUM 24.7% 1-Year Est. Return
RIM
Rockbridge Investment Management Syracuse, New York $1.11B AUM 13.62% 1-Year Est. Return
YL
YCG LLC Austin, Texas $1.1B AUM 4.87% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return

Bain Capital Life Sciences Investors's Q3 2025 Portfolio in Review

As of Q3 2025, Bain Capital Life Sciences Investors held 24 positions worth $1.51B, up 89% from $799M the previous quarter. Its ten largest holdings account for 93% of the portfolio.

Bain Capital Life Sciences Investors deployed $262M of net new capital in Q3 2025, opening 1 new position and adding to 2 existing holdings. Its largest new stake was Heartflow Inc: 12,448,158 shares worth $419M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, down from 100% a quarter earlier.

On the sell side, the largest reduction was Dianthus Therapeutics, an estimated $29.8M trimmed.

  • Bain Capital Life Sciences Investors's largest Q3 2025 buy was Heartflow Inc: 12,448,158 shares worth $419M.
  • Bain Capital Life Sciences Investors added most to Cidara Therapeutics in Q3 2025, an estimated $33.2M increase.
  • Bain Capital Life Sciences Investors's biggest Q3 2025 reduction was Dianthus Therapeutics, cutting an estimated $29.8M.
  • Bain Capital Life Sciences Investors fully exited Nuvalent in Q3 2025, selling an estimated $110M.
  • Bain Capital Life Sciences Investors's ten largest holdings make up 93% of its $1.51B portfolio in Q3 2025.
  • Bain Capital Life Sciences Investors opened 1 new position and closed 3 in Q3 2025.
  • Bain Capital Life Sciences Investors's portfolio value rose 89% quarter-over-quarter to $1.51B.

Based on Bain Capital Life Sciences Investors's 13F filing for Q3 2025, filed 14 Nov 2025.